131I-MIBG + dinutuximab

131I-MIBG + dinutuximab is a **combination investigational therapy** for relapsed or refractory high-risk neuroblastoma, primarily in pediatric patients. - **131I-metaiodobenzylguanidine (131I-MIBG):** a radiopharmaceutical that selectively targets neuroblastoma cells via norepinephrine transporter-mediated uptake, delivering targeted beta-emitting radiation to tumor sites. - **Dinutuximab:** a chimeric monoclonal IgG1 antibody that binds the glycolipid disialoganglioside GD2, highly expressed on neuroblastoma cells, mediating cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) mechanisms[3][4][8]. Preclinical and early clinical studies demonstrate that combining 131I-MIBG with dinutuximab yields synergistic antitumor effects, potentially improving response rates and outcomes in heavily pretreated, high-risk neuroblastoma[3][5][9]. In phase I trials, this regimen showed tolerability and encouraging antitumor activity (best overall response rate ~42%), with further enhancement when combined with the HDAC inhibitor vorinostat[5][9].

Brand names

Unituxin

Other names

131I-metaiodobenzylguanidine + dinutuximabI-131 MIBG + dinutuximabch14.18 (for dinutuximab)